See more : Sunsweet Public Company Limited (SUN.BK) Income Statement Analysis – Financial Results
Complete financial analysis of Bellicum Pharmaceuticals, Inc. (BLCM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bellicum Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Performance Shipping Inc. (PSHG) Income Statement Analysis – Financial Results
- HFCL Limited (HFCL.NS) Income Statement Analysis – Financial Results
- QinetiQ Group plc (QNTQF) Income Statement Analysis – Financial Results
- Hua Yin International Holdings Limited (0989.HK) Income Statement Analysis – Financial Results
- Stadio Holdings Limited (SDO.JO) Income Statement Analysis – Financial Results
Bellicum Pharmaceuticals, Inc. (BLCM)
About Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes in the treatment of leukemias, lymphomas, and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in Houston, Texas.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.50M | 6.20M | 500.00K | 7.14M | 1.12M | 185.00K | 388.00K | 282.00K | 1.78M | 1.94M | 1.47M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.50M | 6.20M | 500.00K | 7.14M | 1.12M | 185.00K | 388.00K | 282.00K | 1.78M | 1.94M | 1.47M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 22.76M | 23.58M | 39.05M | 64.54M | 71.15M | 65.66M | 51.26M | 33.56M | 11.01M | 7.05M | 5.80M |
| General & Administrative | 5.72M | 7.01M | 15.53M | 29.97M | 25.43M | 21.91M | 17.51M | 15.86M | 5.40M | 2.81M | 1.94M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.72M | 7.01M | 15.53M | 29.97M | 25.43M | 21.91M | 17.51M | 15.86M | 5.40M | 2.81M | 1.94M |
| Other Expenses | 0.00 | 7.00K | 112.00K | -2.99M | 436.00K | 864.00K | 580.00K | 3.18M | 43.21B | 0.00 | 0.00 |
| Operating Expenses | 28.48M | 30.59M | 54.58M | 94.51M | 96.59M | 87.57M | 68.77M | 49.42M | 16.41M | 9.86M | 7.74M |
| Cost & Expenses | 28.48M | 30.59M | 54.58M | 94.51M | 96.59M | 87.57M | 68.77M | 49.42M | 16.41M | 9.86M | 7.74M |
| Interest Income | 0.00 | 32.00K | 387.00K | 1.35M | 1.64M | 1.06M | 909.00K | 641.00K | 34.98K | 3.92K | 7.55K |
| Interest Expense | 46.00 | 4.00K | 2.66M | 4.28M | 4.20M | 3.67M | 1.76M | 12.00K | 1.76M | 50.72K | 1.41K |
| Depreciation & Amortization | -1.95M | 517.00K | -1.89M | 19.19M | 6.70M | 3.56M | 2.31M | 1.20M | 666.61K | 587.25K | 115.28K |
| EBITDA | -26.98M | -24.35M | 2.39M | -87.36M | -95.47M | -82.77M | -68.38M | -47.30M | -57.84B | -7.33M | -6.15M |
| EBITDA Ratio | -1,928.93% | -392.73% | -10,716.80% | -954.39% | -8,523.75% | -44,739.46% | -17,623.71% | -16,771.28% | -821.69% | -377.75% | -418.02% |
| Operating Income | -26.98M | -24.87M | -51.69M | -87.36M | -95.47M | -87.39M | -68.38M | -49.14M | -57.84M | -7.92M | -6.27M |
| Operating Income Ratio | -1,798.73% | -401.06% | -10,338.40% | -1,223.07% | -8,523.75% | -47,236.22% | -17,623.71% | -17,423.76% | -3,249.33% | -408.21% | -426.37% |
| Total Other Income/Expenses | 2.01M | 15.16M | -10.11M | -25.11M | -2.57M | -4.39M | -861.00K | 587.00K | -26.13M | -46.80K | 6.14K |
| Income Before Tax | -24.97M | -9.71M | -7.72M | -112.48M | -98.04M | -91.78M | -69.24M | -48.55M | -83.97M | -7.97M | -6.26M |
| Income Before Tax Ratio | -1,664.73% | -156.53% | -1,544.40% | -1,574.65% | -8,753.21% | -49,610.27% | -17,845.62% | -17,215.60% | -4,717.13% | -410.62% | -425.96% |
| Income Tax Expense | 2.00K | -127.00K | 897.00K | 13.62M | 1.63M | 3.67M | -1.46M | 12.00K | 1.09M | 3.92K | 7.55K |
| Net Income | -24.97M | -9.58M | -8.62M | -126.09M | -98.04M | -91.78M | -69.24M | -48.55M | -83.97M | -7.97M | -6.26M |
| Net Income Ratio | -1,664.87% | -154.48% | -1,723.80% | -1,765.25% | -8,753.21% | -49,610.27% | -17,845.62% | -17,215.60% | -4,717.13% | -410.62% | -425.96% |
| EPS | -0.81 | -0.83 | -1.50 | -26.92 | -24.37 | -28.94 | -25.69 | -18.43 | -33.47 | -8.11 | -6.37 |
| EPS Diluted | -0.81 | -0.83 | -1.50 | -26.92 | -24.37 | -28.94 | -25.69 | -18.43 | -33.47 | -8.11 | -6.37 |
| Weighted Avg Shares Out | 30.83M | 11.50M | 5.76M | 4.68M | 4.02M | 3.17M | 2.70M | 2.63M | 2.51M | 982.78K | 982.78K |
| Weighted Avg Shares Out (Dil) | 30.83M | 11.50M | 5.76M | 4.68M | 4.02M | 3.17M | 2.70M | 2.63M | 2.51M | 982.78K | 982.78K |
Talented musician drowned in Merlin's Cave following Tintagel fairy ball
The 23-year-old care worker 'would help anyone'
Bellicum Pharmaceuticals to Participate in Three Healthcare Investor Conferences during September
HOUSTON, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that senior management will participate in three upcoming healthcare investor conferences.
Bellicum Pharmaceuticals Announces Aggregate Gross Proceeds of $69.6 Million from $139.6 Million Public Offering and Private Placement
Closing of $57.5 Million Public Offering of Preferred Stock and Warrants and Receipt of $12.1 Million Option Fee Related to Private Placement of up to $70.0 Million of Preferred Stock and Warrants Closing of $57.5 Million Public Offering of Preferred...
BELLICUM LEAD PLAINTIFF ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 in Bellicum Pharmaceuticals, Inc. to Contact the Firm
NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Bellicum Pharmaceuticals, Inc. (“Bellicum” or the “Company”) (NASDAQ:BLCM) of the April 9, 2018 deadline to seek the role of lead plaintiff in a federal securities...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bellicum Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – BLCM
NEW YORK--(BUSINESS WIRE)--Pomerantz LLP announces that a class action lawsuit has been filed against Bellicum Pharmaceuticals, Inc. (“Bellicum” or the “Company”) (NASDAQ: BLCM) and certain of its officers. The class action, filed in United States District Court, for the Southern...
Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Bellicum Pharmaceuticals, Inc.
SAN DIEGO--(BUSINESS WIRE)--Robbins Geller Rudman & Dowd LLP (“Robbins Geller”) (http://www.rgrdlaw.com/cases/bellicum/) today announced that a class action has been commenced on behalf of purchasers of Bellicum Pharmaceuticals, Inc. (“Bellicum”) (NASDAQ:BLCM) securities during the period between May 8, 2017 and January...
DEADLINE ALERT: Brower Piven Reminds Investors of Upcoming Deadline in Class Action Lawsuit and Encourages Shareholders Who Have Losses in Excess of $100,000 from Investment in Bellicum Pharmaceuticals, Inc. to Contact the Firm
STEVENSON, Md.--(BUSINESS WIRE)--The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of Texas on behalf of purchasers of Bellicum...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in Bellicum Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – BLCM
NEW YORK--(BUSINESS WIRE)--Pomerantz LLP announces that a class action lawsuit has been filed against Bellicum Pharmaceuticals, Inc. (“Bellicum” or the “Company”) (NASDAQ: BLCM) and certain of its officers. The class action, filed in United States District Court, for the Southern...
BELLICUM INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing in Bellicum Pharmaceuticals, Inc. to Contact the Firm
NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Bellicum Pharmaceuticals, Inc. (“Bellicum” or the “Company”) (NASDAQ:BLCM). Aftermarket on January 30, 2018, Bellicum issued a press release entitled “Bellicum Pharmaceuticals Announces Clinical...
BELLICUM INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Bellicum Pharmaceuticals, Inc. To Contact The Firm
NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Bellicum Pharmaceuticals, Inc. (“Bellicum” or the “Company”) (NASDAQ:BLCM). Aftermarket on January 30, 2018, Bellicum issued a press release entitled “Bellicum Pharmaceuticals Announces Clinical...
Source: https://incomestatements.info
Category: Stock Reports